BRCA1 and cancer: The rising interest in APE2 as a drug target for precision medicine in chemotherapy is largely due to the multiple reports of its SL with BRCA1- and BRCA2-deficient cell lines (10,25,26), suggesting that inhibiting APE2 may lead to the loss of viability in BRCA1/2-deficient cancer cells (Figure 6A).